Latest Period
Q4 2025
Security Snapshot
Atara Biotherapeutics, Inc. - Common Stock (ATRA) Institutional Ownership
CUSIP: 046513107
13F Institutional Holders and Ownership History from Q4 2014 to Q4 2025
Institutions Reporting
0
Shares (Excl. Options)
0
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- ATRA on Nasdaq
- Shares outstanding
- 8,165,808
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 0
- Total reported value
- $0
- Share change
- -15
- Value change
- -$215
- Number of holders
- 0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ATRA - Atara Biotherapeutics, Inc. - Common Stock is tracked under CUSIP 046513107.
- 0 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
- Reported value moved from $215 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 0 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 046513107?
CUSIP 046513107 identifies ATRA - Atara Biotherapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 046513107:
Significant Owners of Atara Biotherapeutics, Inc. - Common Stock (ATRA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Panacea Innovation Ltd | 20% | -0.05% | -$1,154,619 | 1,632,345 | -4.7% | Panacea Innovation Limited | 12 Jan 2026 | |
| Adiumentum Capital Fund I LP | 20% | 1,370,081 | Adiumentum Capital Fund I LP | 14 May 2025 |
As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of Atara Biotherapeutics, Inc. - Common Stock (ATRA). This represents 0% of the company’s total 8,165,808 outstanding shares.
Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$215 | 0 | |
| 2025 Q3 | 15 | $215 | +$215 | $14.33 | 1 |
| 2025 Q1 | 0 | $0 | -$839 | 0 | |
| 2024 Q4 | 63 | $839 | $13.32 | 2 | |
| 2024 Q3 | 35 | $285 | -$1,511,256 | $8.14 | 1 |
| 2024 Q2 | 182,077 | $1,511,600 | -$88,647,049 | $8.50 | 5 |
| 2024 Q1 | 83,249,933 | $57,775,105 | +$13,539,594 | $0.69 | 80 |
| 2023 Q4 | 64,725,654 | $33,190,425 | -$41,739,808 | $0.51 | 89 |
| 2023 Q3 | 88,187,935 | $130,517,483 | -$3,294,604 | $1.48 | 108 |
| 2023 Q2 | 90,354,566 | $145,469,168 | -$23,260,244 | $1.61 | 115 |
| 2023 Q1 | 102,693,551 | $297,884,697 | +$14,378,615 | $2.90 | 124 |
| 2022 Q4 | 97,400,862 | $319,467,221 | -$2,173,205 | $3.28 | 138 |
| 2022 Q3 | 97,668,961 | $369,193,024 | -$18,917,474 | $3.78 | 149 |
| 2022 Q2 | 99,815,040 | $777,439,383 | +$14,024,584 | $7.79 | 132 |
| 2022 Q1 | 97,877,569 | $909,405,142 | +$12,542,757 | $9.29 | 139 |
| 2021 Q4 | 93,317,058 | $1,470,768,390 | +$63,749,519 | $15.76 | 137 |
| 2021 Q3 | 87,844,034 | $1,572,372,278 | +$69,603,688 | $17.90 | 138 |
| 2021 Q2 | 85,946,359 | $1,336,531,861 | -$10,054,279 | $15.55 | 144 |
| 2021 Q1 | 85,650,758 | $1,229,931,921 | -$3,128,334 | $14.36 | 148 |
| 2020 Q4 | 86,646,814 | $1,700,929,395 | +$61,203,871 | $19.63 | 144 |
| 2020 Q3 | 83,809,041 | $1,086,847,081 | +$59,533,643 | $12.96 | 138 |
| 2020 Q2 | 77,585,671 | $1,130,387,589 | +$244,721,751 | $14.57 | 121 |
| 2020 Q1 | 62,604,589 | $531,867,879 | +$2,830,287 | $8.51 | 106 |
| 2019 Q4 | 61,123,347 | $1,006,681,660 | +$38,331,911 | $16.47 | 112 |
| 2019 Q3 | 59,009,784 | $833,183,512 | +$118,059,357 | $14.12 | 111 |
| 2019 Q2 | 50,296,513 | $1,011,718,530 | +$11,334,650 | $20.11 | 114 |
| 2019 Q1 | 48,808,849 | $1,940,163,733 | +$25,166,384 | $39.75 | 118 |
| 2018 Q4 | 48,253,940 | $1,676,297,014 | +$62,510,625 | $34.74 | 119 |
| 2018 Q3 | 46,348,347 | $1,916,490,444 | -$3,168,582 | $41.35 | 114 |
| 2018 Q2 | 46,455,501 | $1,707,224,921 | +$103,228,229 | $36.75 | 122 |
| 2018 Q1 | 43,618,390 | $1,698,364,623 | +$561,989,584 | $39.00 | 113 |
| 2017 Q4 | 29,837,777 | $541,854,369 | +$35,717,603 | $18.10 | 82 |
| 2017 Q3 | 26,588,544 | $441,130,415 | +$15,294,795 | $16.55 | 80 |
| 2017 Q2 | 25,741,068 | $360,377,428 | +$19,806,324 | $14.00 | 80 |
| 2017 Q1 | 23,968,978 | $492,552,713 | +$57,013,769 | $20.55 | 82 |
| 2016 Q4 | 23,232,402 | $329,896,488 | +$8,113,819 | $14.20 | 83 |
| 2016 Q3 | 22,400,142 | $479,016,785 | +$15,346,848 | $21.39 | 72 |
| 2016 Q2 | 21,590,915 | $486,014,073 | +$46,726,583 | $22.51 | 70 |
| 2016 Q1 | 19,799,648 | $376,755,000 | +$7,120,067 | $19.03 | 69 |
| 2015 Q4 | 19,264,140 | $508,636,288 | -$21,986,693 | $26.41 | 83 |
| 2015 Q3 | 19,482,171 | $612,517,952 | +$196,917,062 | $31.44 | 87 |
| 2015 Q2 | 13,191,481 | $695,961,994 | +$107,658,520 | $52.76 | 74 |
| 2015 Q1 | 11,227,473 | $461,513,969 | +$185,585,180 | $41.57 | 52 |
| 2014 Q4 | 6,725,410 | $172,103,401 | +$161,930,701 | $26.75 | 39 |